Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...
Clinical Advisor2d
Patients With Skin of Color Have More Severe Rosacea Phenotypes
Investigators sought to better understand how race and ethnicity was related to the severity of rosacea phenotypes among adults.
Journey Medical launches Emrosi for the treatment of rosacea
Journey Medical (DERM) announced the launch of and the first prescriptions filled for Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended ...
MPR3d
Emrosi Now Available for the Treatment of Rosacea
Emrosi™ (minocycline hydrochloride extended-release capsules) is now available for the treatment of inflammatory lesions (papules and pustules) of rosacea ...